There has been a growing trend of life science manufacturers collaborating with local governments (e.g., at the municipal and prefectural level) in Japan during the past 3-5 years. This trend is observed not only with domestic manufacturers but among foreign…
HOME > BUSINESS
BUSINESS
- Shionogi Starts Document Submission for COVID Pill in China
July 5, 2022
- BMS Japan Launches New Head Office as It Looks to Spur Ideas through Casual Chats
July 5, 2022
- High Court Verdict for Bayer Employee Damage Suit Set for Sept. 7, Settlement Eyed Too
July 5, 2022
- Aculys, KNOCK ON THE DOOR Form Comprehensive Epilepsy Alliance
July 5, 2022
- Promotions via In-Hospital Seminars in HP Market Rise 28.4% YOY in May: Intage
July 5, 2022
- Chugai Best-Paying Japan Pharma in FY2021, 25 Drug Makers Pay Average 8.33 Million Yen
July 4, 2022
- UCB Japan Snaps Up Zogenix Japan, Employees Too
July 4, 2022
- AstraZeneca Japan Taps Ex-Takeda Japan Oncology Head as New Chief
July 4, 2022
- Fujifilm to Inject US$1.6 Billion to Rev Up Biopharma CDMO Biz
July 1, 2022
- Mitsubishi Tanabe Seeks Congenital CMV Nod for Valixa Dry Syrup
July 1, 2022
- AbbVie Japan Files Skyrizi for Palmoplantar Pustulosis
July 1, 2022
- Blood Cancer Drug Pegaspargase Filed in Japan: Nihon Servier
July 1, 2022
- Sanofi Seeks Dupixent Label Expansion for Prurigo Nodularis in Japan
July 1, 2022
- 37 Pharma Execs Get 100 Million-Plus Yen in FY2021, Top 3 at Takeda: Securities Reports
July 1, 2022
- Despite 4 Trillion Yen Debt, Takeda CEO Confident in Deleveraging, Pipeline Boost, Shareholder Returns
June 30, 2022
- Pfizer Seeks Japan Approval of Aplastic Anemia Med
June 30, 2022
- Tissue-Engineering Market in Asia to Hit 712 Billion Yen in 2030: Fuji Keizai
June 30, 2022
- Takeda CEO’s Pay Down to 1.86 Billion Yen in FY2021
June 30, 2022
- Wholesalers Bear Over 50 Billion Yen in Annual Costs Tied to Restricted Drug Supply: Crecon Estimate
June 29, 2022
- Astellas/Sutro to Codevelop Next-Gen Immunostimulatory ADCs for Cold Tumors
June 29, 2022
ページ
Shionogi’s COVID-19 pill ensitrelvir failed to clear the second round of review by a key advisory panel on July 20. The session drew a great deal of attention since the drug is the first candidate for the application of Japan’s…
The average ratio of females in managerial posts at Japanese drug makers has finally reached a double-digit number, at 10.0%, a Jiho survey found. However, this is still well below a near-25% ratio logged by foreign players operating in the…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…
A total of 15 new drugs (APIs) joined the NHI price list in 2021 with peak sales forecasts topping at 10 billion yen, many of them in the area of orphan diseases and with few mega launches, according to a…